secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2024-12-19T23:59:59+00:00
Accession:  0001104659-24-129981
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Armata Pharmaceuticals Announces Phase 2 Tailwind Study Results for Inhaled AP-PA02 in NCFB Subjects
--------------------------------------------------------------------------------

- Post-hoc analysis showed statistically significant reduction of P.a. CFUs at day 17 (P=0.05) and day 24 (P=0.015).
- Approximately one-third of AP-PA02 monotherapy subjects achieved at least a 2-log CFU reduction versus none on placebo.
- Inhaled AP-PA02 was well-tolerated with mild, self-limiting adverse events; one possibly related serious adverse event reported.
- AP-PA02 is a novel multi-phage therapeutic for chronic Pseudomonas aeruginosa infections in non-cystic fibrosis bronchiectasis.
- Results suggest AP-PA02 monotherapy may be as effective as combination with anti-pseudomonal antibiotics in reducing lung P.a. burden.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465924129981/0001104659-24-129981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465924129981/tm2431487d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-129981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer